Product Description
LB03002 is a novel, sustained-release recombinant human GH, developed for once-a-week s.c. injection. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/19074465/)
Mechanisms of Action: GHR Agonist
Novel Mechanism: No
Modality: Coagulation Factor
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BioPartners
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Deficiency Diseases|Pituitary Diseases|Dwarfism, Pituitary|Hypopituitarism|Other
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2005-000346-36 |
2005-000346-36 | P3 |
Completed |
Other |
None |
2025-07-02 |
||
2006-002278-24 |
2006-002278-24 | P3 |
Completed |
Hypopituitarism |
2008-09-05 |
2025-07-02 |
Treatments |
|
NCT00596037 |
BPLG-005-RO | P3 |
Completed |
Pituitary Diseases|Deficiency Diseases|Hypopituitarism|Dwarfism, Pituitary |
2008-09-01 |
2019-03-18 |
Treatments |
|
2005-000384-26 |
2005-000384-26 | P3 |
Completed |
Hypopituitarism |
2008-03-04 |
2022-03-12 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|